Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00917059
Recruitment Status : Completed
First Posted : June 10, 2009
Last Update Posted : February 6, 2013
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Ian A. Cook, M.D., University of California, Los Angeles

June 8, 2009
June 10, 2009
February 6, 2013
May 2009
May 2012   (Final data collection date for primary outcome measure)
Score on Hamilton Depression Rating Scale (HAM-D) [ Time Frame: Measured nine times over 8 weeks ]
Same as current
Complete list of historical versions of study NCT00917059 on Archive Site
Score on Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) [ Time Frame: Measured nine times over 8 weeks ]
Same as current
Not Provided
Not Provided
Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study)
Personalized Response Indicators of SSRI Effectiveness in Major Depression
This study will examine whether measures of brain electrical signals taken after a week of antidepressant medication treatment can predict whether a full treatment regimen will be effective.

Major depressive disorder (MDD) is a common psychiatric illness with a high cost to society and individual patients. Initial medication treatments for MDD are often ineffective, precipitating a need to try other medications. This extends suffering, continues functional disability, and increases both the risk of relapse and the risk that people will abandon treatment. Having a biological marker of likely treatment effectiveness to predict and guide clinicians' decisions would reduce the likelihood of people with MDD experiencing unsuccessful treatments. This study will test whether quantitative electroencephalogram (QEEG) measures taken after 1 week of medication treatment can predict effectiveness of a full treatment regimen with depression medications.

Participation in this study will last 8 weeks. At the first study visit, participants will undergo baseline assessments. These assessments will include an interview about present condition, medical and psychiatric history, and past and current medication treatments; a urine test; and questionnaires about depression symptoms and other possible symptoms. The study doctor may ask for other assessments based on each participant's individual profile.

Participants will then complete a 1-week treatment with escitalopram, a type of antidepressant medication called a selective serotonin reuptake inhibitor (SSRI). At the first visit and again after the week-long escitalopram treatment, participants will undergo an electroencephalogram (EEG), which measures brain electrical activity. Based on certain measurements obtained from the EEG, an antidepressant treatment response (ATR) score will be calculated.

Participants will then be divided into two treatment groups: those who continue to receive escitalopram and those who begin treatment with bupropion XL, a non-SSRI antidepressant medication. Treatment for both groups will last 8 weeks, during which time participants will attend seven study visits. At these study visits, participants will be asked about how they are feeling, side effects, and benefit from the treatment. Further tests—such as a physical exam, lab test, or EEG—may be performed if study doctors think they are necessary.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
  • Drug: Escitalopram
    Fixed dose of 10 mg per day
    Other Name: Lexapro
  • Drug: Bupropion XL
    Fixed dose of 150 mg per day
    Other Name: Wellbutrin XL
  • Active Comparator: 1
    Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
    Intervention: Drug: Escitalopram
  • Active Comparator: 2
    Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
    • Drug: Escitalopram
    • Drug: Bupropion XL
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
May 2012
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets DSM-IV criteria for diagnosis of major depressive disorder (MDD) based on the Mini-International Neuropsychiatric Interview (MINI)
  • Score greater than or equal to 12 on the Quick Inventory of Depressive Symptomatology - Self Rated version (QIDS-SR16)

Exclusion Criteria:

  • Serious or unstable medical illness that would prevent complete participation in the trial, determined as needed from physical examination, electrocardiogram (ECG), laboratory safety tests, and review of systems
  • Mentally or legally incapacitated and therefore unable to give informed consent
  • Meets DSM-IV criteria for anorexia nervosa, bulimia nervosa, obsessive-compulsive disorder, any cognitive disorder, bipolar disorder, psychotic disorder, or major depression with psychotic features
  • Diagnosis of a DSM-IV axis II disorder that would interfere with completion of the protocol
  • Would have met criteria for a diagnosis of drug dependency or substance abuse within the preceding 9 months
  • Stable and in remission on current psychotropic medication(s)
  • Has had a course of electroconvulsive therapy (ECT) within the past 6 months
  • Started psychotherapy for the current depressive episode within the past 2 months
  • Has experienced treatment failure with an adequate trial of any study medication during the current episode of depression or has failed to tolerate escitalopram in the current episode
  • Known contraindication for use of any of the study drugs, including hyponatremia during past use of a selective serotonin reuptake inhibitor (SSRI)
  • Treated with fluoxetine or a monoamine oxidase inhibitor (MAOI) within the past 4 weeks
  • Presence of a serious or unstable medical illness, including heart, liver, kidney, respiratory, endocrine, neurologic, or blood disease severe enough to significantly affect brain function or to interfere with interpretation of study results
  • History of seizures, brain surgery, skull fracture, significant head trauma, or abnormal electroencephalogram (EEG)
  • Currently pregnant or of childbearing potential and not using a medically acceptable means of birth control (e.g., oral contraceptive pill or implant, condom, diaphragm, spermicide, intrauterine device [IUD], past tubal ligation, partner with vasectomy)
  • Breastfeeding
  • University student or staff member directly under instruction, supervision, or employment of any of the investigators
  • Requires hospitalization (e.g., poses an imminent danger to self or others)
  • Initial quantitative EEG (QEEG) is contaminated with artifact so that determination of the biomarker is precluded
  • Use of medications known to affect brain function
Sexes Eligible for Study: All
21 Years to 75 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
R01MH085925( U.S. NIH Grant/Contract )
R01MH085925 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Ian A. Cook, M.D., University of California, Los Angeles
University of California, Los Angeles
National Institute of Mental Health (NIMH)
Principal Investigator: Ian A. Cook, MD University of California, Los Angeles
University of California, Los Angeles
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP